Dalacin c

Postoperatively, antibiotic therapy (Penicillin with Clavulanic acid 2 × 1000 mg/day; Augmentin Duo, GlaxoSmithKline, Brentford, UK) and non-steroidal anti-inflammatory drugs (Diclofenac-Sodium 4 × 50 mg/day; Cataflam, Novartis International AG, Basel, Switzerland) were prescribed for 1 week in order to avoid infections and to decrease swelling and pain. In case of penicillin allergy, Clindamycin (Dalacin C, Pfizer, New York, USA) 4 × 300 mg per day was prescribed. Patients were instructed to gently brush teeth at surgical sites with a soft manual toothbrush. For chemical plaque control, 0.2% chlorhexidine digluconate mouthwash (Curasept ADS 220, Curaden AG, Kriens, Switzerland) was prescribed twice a day. Mucosal sutures were removed 7 days, periosteal sutures 14 days after surgery. Following suture removal, patients were scheduled for recall visits weekly in the first month, followed by visits every 3 months postoperatively. Patients received fixed partial dentures 2 weeks after implant uncovering. After delivery of the final prosthetic reconstructions, patients were enrolled in a periodontal maintenance program.

After implant placement, systemic antibiotic therapy (penicillin with clavulanic acid 2 × 1000 mg/day; Augmentin Duo, GlaxoSmithKline, Brentford, UK), and non-steroidal anti-inflammatory drugs (diclofenac-sodium 4 × 50 mg/day; Cataflam, Novartis International AG, Basel, Switzerland) were prescribed for 7 days in order to avoid infections and to decrease swelling and pain. In case of penicillin allergy, 4 × 300 mg/day clindamycin (Dalacin C, Pfizer, New York, USA) was administered for 7 days. For chemical plaque control, 0.2% chlorhexidine digluconate mouthrinse (Curasept ADS 220, Curaden AG, Kriens, Switzerland) was prescribed 3 times a day. After the delivery of screw-retained fixed partial dentures, the patients were enrolled in a periodontal maintenance program.